Jillian Dilmore - 15 Jun 2022 Form 4 Insider Report for Baudax Bio, Inc.

Role: Corporate Controller/Secretary, PFO and PAO
Signature: /s/ Jillian Dilmore
Issuer symbol: N/A
Transactions as of: 15 Jun 2022
Net transactions value: $0
Form type: 4
Filing time: 17 Jun 2022, 16:11:51 UTC
Previous filing: 26 Apr 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BXRX	Common Stock	Award	$0	+15,467	+5707%	$0.000000	15,738	15 Jun 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Stock Unit ("RSU") is the economic equivalent of one share of Baudax Bio, Inc. (the "Company") common stock, and may be settled, at the Company's option, in cash, shares of common stock, or a combination thereof. The RSUs vest 50% on June 15, 2023 and 50% on June 15, 2024, in each case subject to continued service with the Company through the applicable vesting date. Upon vesting, if settled in cash, each RSU will entitle the grantee to a cash-payment equal to the "Fair Market Value" (as defined in the Company's 2019 Equity Incentive Plan) of one share of the Company's common stock on the applicable vesting date.

Content

Each Restricted Stock Unit ("RSU") is the economic equivalent of one share of Baudax Bio, Inc. (the "Company") common stock, and may be settled, at the Company's option, in cash, shares of common stock, or a combination thereof. The RSUs vest 50% on June 15, 2023 and 50% on June 15, 2024, in each case subject to continued service with the Company through the applicable vesting date. Upon vesting, if settled in cash, each RSU will entitle the grantee to a cash-payment equal to the "Fair Market Value" (as defined in the Company's 2019 Equity Incentive Plan) of one share of the Company's common stock on the applicable vesting date.